1 |
Ruggeri RM, Benevento E, De Cicco F, Fazzalari B, Guadagno E, Hasballa I, Tarsitano MG, Isidori AM, Colao A, Faggiano A; NIKE Group. Neuroendocrine neoplasms in the context of inherited tumor syndromes: a reappraisal focused on targeted therapies. J Endocrinol Invest 2023;46:213-34. [PMID: 36038743 DOI: 10.1007/s40618-022-01905-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
2 |
Malandrino P, Mazzilli R, Puliani G, Di Molfetta S, Pugliese G, Olana S, Colao AM, Faggiano A, On Behalf Of The Nike Group. The Effects of Radioligand Therapy on Quality of Life and Sexual Function in Patients with Neuroendocrine Neoplasms. Cancers (Basel) 2022;15. [PMID: 36612112 DOI: 10.3390/cancers15010115] [Reference Citation Analysis]
|
3 |
Fu M, Yu L, Yang L, Chen Y, Chen X, Hu Q, Sun H. Gender differences in pancreatic neuroendocrine neoplasms: A retrospective study based on the population of Hubei Province, China. Front Endocrinol 2022;13:885895. [DOI: 10.3389/fendo.2022.885895] [Reference Citation Analysis]
|
4 |
Zamponi V, La Salvia A, Tarsitano MG, Mikovic N, Rinzivillo M, Panzuto F, Giannetta E, Faggiano A, Mazzilli R. Effect of Neuroendocrine Neoplasm Treatment on Human Reproductive Health and Sexual Function. J Clin Med 2022;11:3983. [PMID: 35887747 DOI: 10.3390/jcm11143983] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|